A Rare Case of Severe Skin Reaction to Mycophenolate Mofetil in Systemic Lupus Erythematosus with Lupus Nephritis
We report a rare case of a severe maculopapular rash following the initiation of mycophenolate mofetil MMF in a 13-year-old female adolescent who was diagnosed with systemic lupus erythematosus SLE and stage...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Rajiv Gandhi University of Health Sciences
2025-01-01
|
| Series: | RGUHS Journal of Medical Sciences |
| Online Access: |
https://journalgrid.com/view/article/rjms/12434457 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | We report a rare case of a severe maculopapular rash
following the initiation of mycophenolate mofetil MMF in a 13-year-old
female adolescent who was diagnosed with systemic lupus erythematosus SLE
and stage IV lupus nephritis. MMF an effective immunosuppressive agent
selectively inhibits T and B lymphocyte proliferation and is known for its
rapid onset and relatively mild side effect profile compared to other
immunosuppressants. The patient was initially treated with intravenous and
oral prednisolone along with hydroxychloroquine followed by introduction of
mycophenolate mofetil two days later. Within 24 hours of starting MMF she
developed an adverse event characterized by a maculopapular rash with
blisters intense itching facial puffiness and swelling of the lips.
High-dose steroids and discontinuation of MMF led to gradual improvement
with complete resolution of symptoms within two days. The diagnosis of a
druginduced eruption was supported by symptom resolution and a marked
response to steroids. While common side effects of MMF include
gastrointestinal disturbances and peripheral oedema severe skin reactions
are infrequent. Given the overall prevalence of MMF use we present a rare
case of generalised maculopapular rash caused by MMF. This case highlights
the adverse event caused by MMF in the context of SLE and lupus nephritis
underscoring the need for vigilant monitoring of patients receiving this
treatment. |
|---|---|
| ISSN: | 2231-1947 2581-7248 |